Literature DB >> 17567467

Role of innate immune response in liver regeneration.

Yuji Iimuro1, Ekihiro Seki, Gakuhei Son, Hiroko Tsutsui, Kenji Nakanishi, Jiro Fujimoto.   

Abstract

Liver regeneration following partial hepatectomy (PH) requires several steps including innate immune responses, particularly interleukin-6 (IL-6) and tumor necrosis factor-(TNF-)alpha production by Kupffer cells, although the activation processes are still unknown. Toll-like receptors (TLR) act as innate immune signal sensors and play central roles in host defense. Myeloid differentiation factor (MyD) 88 is a common adaptor molecule required for signaling mediated by TLR. When the receptors are activated, cells bearing TLR produce various pro-nflammatory cytokines in a MyD88-dependent manner. The authors investigated whether TLR/MyD88 signaling is critical for induction of innate immune responses after PH. In Myd88(-/-) mice after PH, induction of expression of immediate early genes involved in hepatocyte replication and phosphorylation of signal transducer and activators of transcription 3 (STAT3) in the liver, and production of TNF-alpha/IL-6 by and activation of NF-kappaB in the Kupffer cells were grossly subnormal and were associated with impaired liver regeneration, while TLR2, 4 and 9, which recognize Gram-negative and -positive bacterial products, are not essential for NF-kappaB activation and IL-6 production after PH. In conclusion, the TLR/MyD88 pathway is essential for liver restoration after PH, particularly its early phase.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17567467     DOI: 10.1111/j.1440-1746.2006.04651.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  8 in total

1.  MTA1 coregulator regulates LPS response via MyD88-dependent signaling.

Authors:  Suresh B Pakala; Sirigiri Divijendra Natha Reddy; Tri M Bui-Nguyen; Siddharth S Rangparia; Anitha Bommana; Rakesh Kumar
Journal:  J Biol Chem       Date:  2010-08-11       Impact factor: 5.157

2.  Expression of pattern recognition receptor genes and mortality in patients with colorectal adenocarcinoma.

Authors:  Kathryn E Royse; Liang Chen; David H Berger; Michael M Ittmann; Hashem B El-Serag; Courtney J Balentine; David Y Graham; Peter A Richardson; Rolando E Rumbaut; Xiaoyun Shen; Donna L White; Li Jiao
Journal:  Int J Mol Epidemiol Genet       Date:  2017-04-15

3.  Deficiency of the myeloid differentiation primary response molecule MyD88 leads to an early and rapid development of Helicobacter-induced gastric malignancy.

Authors:  Anirban Banerjee; Soracha Thamphiwatana; Ellese M Carmona; Barry Rickman; Kelly S Doran; Marygorret Obonyo
Journal:  Infect Immun       Date:  2013-10-28       Impact factor: 3.441

Review 4.  MyD88 and its divergent toll in carcinogenesis.

Authors:  Rosalba Salcedo; Christophe Cataisson; Uzma Hasan; Stuart H Yuspa; Giorgio Trinchieri
Journal:  Trends Immunol       Date:  2013-05-07       Impact factor: 16.687

5.  Liver Regeneration after Partial Hepatectomy Is Not Impaired in Mice with Double Deficiency of Myd88 and IFNAR Genes.

Authors:  Javier Vaquero; Kimberly J Riehle; Nelson Fausto; Jean S Campbell
Journal:  Gastroenterol Res Pract       Date:  2011-12-19       Impact factor: 2.260

Review 6.  Bacterial Signaling at the Intestinal Epithelial Interface in Inflammation and Cancer.

Authors:  Olivia I Coleman; Dirk Haller
Journal:  Front Immunol       Date:  2018-01-05       Impact factor: 7.561

7.  Omeprazole Increases Survival Through the Inhibition of Inflammatory Mediaters in Two Rat Sepsis Models.

Authors:  Masaya Kotsuka; Yuki Hashimoto; Richi Nakatake; Tetsuya Okuyama; Masahiko Hatta; Terufumi Yoshida; Tadayoshi Okumura; Mikio Nishizawa; Masaki Kaibori; Mitsugu Sekimoto
Journal:  Shock       Date:  2022-03-01       Impact factor: 3.454

8.  MyD88 dependent signaling contributes to protective host defense against Burkholderia pseudomallei.

Authors:  W Joost Wiersinga; Catharina W Wieland; Joris J T H Roelofs; Tom van der Poll
Journal:  PLoS One       Date:  2008-10-23       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.